Natalia L Klyachko

List of Publications by Year
in descending order

50	4,928	201385 27	205818 48
papers	citations	h-index	g-index

51	51	51	6038
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of Controlled Release, 2015, 207, 18-30.	4.8	1,363
2	Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 655-664.	1.7	991
3	Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 195-204.	1.7	469
4	Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. Journal of Controlled Release, 2015, 219, 43-60.	4.8	179
5	Macrophage delivery of therapeutic nanozymes in a murine model of Parkinsonâ€™s disease. Nanomedicine, 2010, 5, 379-396.	1.7	154
6	Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy. Journal of NeuroImmune Pharmacology, 2020, 15, 487-500.	2.1	125
7	Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases. PLoS ONE, 2013, 8, e61852.	1.1	124
8	Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials, 2017, 140, 79-87.	5.7	121
9	Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. Journal of Controlled Release, 2012, 162, 636-645.	4.8	99
10	TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease. Advanced Healthcare Materials, 2019, 8, e1801271.	3.9	83
11	Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine, 2014, 9, 1403-1422.	1.7	78
12	Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics. Scientific Reports, 2018, 8, 11295.	1.6	77
13	Cross-linked antioxidant nanozymes for improved delivery to CNS. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 119-129.	1.7	75
14	Bioorganic synthesis in reverse micelles and related systems. Current Opinion in Colloid and Interface Science, 2003, 8, 179-186.	3.4	73
15	Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations. Pharmaceutics, 2020, 12, 1171.	2.0	60
16	In Vitro and In Vivo Electrochemical Measurement of Reactive Oxygen Species After Treatment with Anticancer Drugs. Analytical Chemistry, 2020, 92, 8010-8014.	3.2	58
17	Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine, 2011, 6, 25-42.	1.7	54
18	Changing the Enzyme Reaction Rate in Magnetic Nanosuspensions by a Nonâ€Heating Magnetic Field. Angewandte Chemie - International Edition, 2012, 51, 12016-12019.	7.2	53

#	Article	IF	Citations
19	Blood-borne macrophageâ€“neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery. Nanomedicine, 2012, 7, 815-833.	1.7	51
20	pH-dependent Substrate Preference of Pig Heart Lipoamide Dehydrogenase Varies with Oligomeric State. Journal of Biological Chemistry, 2005, 280, 16106-16114.	1.6	49
21	Theranostic multimodal potential of magnetic nanoparticles actuated by non-heating low frequency magnetic field in the new-generation nanomedicine. Journal of Nanoparticle Research, 2017, 19, 1.	0.8	47
22	Magnetic liposome design for drug release systems responsive to super-low frequency alternating current magnetic field (AC MF). Journal of Colloid and Interface Science, 2019, 552, 689-700.	5.0	45
23	Thermobarostability of Î±-chymotrypsin in reversed micelles of aerosol OT in octane solvated by water-glycerol mixtures. , 1998, 57, 552-556.		38
24	LysK, the enzyme lysing Staphylococcus aureus cells: Specific kinetic features and approaches towards stabilization. Biochimie, 2010, 92, 507-513.	1.3	38
25	In Situ Observation of Chymotrypsin Catalytic Activity Change Actuated by Nonheating Low-Frequency Magnetic Field. ACS Nano, 2018, 12, 3190-3199.	7.3	33
26	Mapping mechanical properties of living cells at nanoscale using intrinsic nanopipetteâ€“sample force interactions. Nanoscale, 2021, 13, 6558-6568.	2.8	33
27	High-pressure stabilization of Î±-chymotrypsin entrapped in reversed micelles of aerosol OT in octane against thermal inactivation. FEBS Letters, 1995, 364, 98-100.	1.3	32
28	Size-selected Fe3O4â€“Au hybrid nanoparticles for improved magnetism-based theranostics. Beilstein Journal of Nanotechnology, 2018, 9, 2684-2699.	1.5	32
29	Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	26
30	Physicochemical characterization of the staphylolytic LysK enzyme in complexes with polycationic polymers as a potent antimicrobial. Biochimie, 2013, 95, 1689-1696.	1.3	23
31	The dynamics of magnetic nanoparticles exposed to non-heating alternating magnetic field in biochemical applications: theoretical study. Journal of Nanoparticle Research, 2017, 19, 1.	0.8	23
32	New Small-Molecule Glycoconjugates of Docetaxel and GalNAc for Targeted Delivery to Hepatocellular Carcinoma. Molecular Pharmaceutics, 2021, 18, 461-468.	2.3	21
33	Non-Heating Alternating Magnetic Field Nanomechanical Stimulation of Biomolecule Structures via Magnetic Nanoparticles as the Basis for Future Low-Toxic Biomedical Applications. Nanomaterials, 2021, 11, 2255.	1.9	21
34	Pressure-Induced Protein Unfolding in the Ternary System AOTâ^'Octaneâ^'Water Is Different from that in Bulk Water. Langmuir, 2005, 21, 3599-3604.	1.6	18
35	Bacteriophage phi11 lysin: Physicochemical characterization and comparison with phage phi80Î± lysin. Enzyme and Microbial Technology, 2015, 73-74, 51-58.	1.6	16
36	A Chimeric LysK-Lysostaphin Fusion Enzyme Lysing Staphylococcus aureus Cells: a Study of Both Kinetics of Inactivation and Specifics of Interaction with Anionic Polymers. Applied Biochemistry and Biotechnology, 2016, 180, 544-557.	1.4	16

#	Article	IF	Citations
37	Magnetic nanorods for remote disruption of lipid membranes by non-heating low frequency magnetic field. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 21, 102065.	1.7	15
38	Superoxide Dismutase 1 Nanoparticles (Nano-SOD1) as a Potential Drug for the Treatment of Inflammatory Eye Diseases. Biomedicines, 2021, 9, 396.	1.4	15
39	Discovery of Bivalent GalNAc-Conjugated Betulin as a Potent ASGPR-Directed Agent against Hepatocellular Carcinoma. Bioconjugate Chemistry, 2021, 32, 763-781.	1.8	12
40	Mannosylated Cationic Copolymers for Gene Delivery to Macrophages. Macromolecular Bioscience, 2021, 21, e2000371.	2.1	12
41	In Vitro/In VivoElectrochemical Detection of Pt(II) Species. Analytical Chemistry, 2022, 94, 4901-4905.	3.2	12
42	Pressure Regulation of Malic Dehydrogenase in Reversed Micelles. Biochemical and Biophysical Research Communications, 1999, 254, 685-688.	1.0	11
43	Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor. Bioconjugate Chemistry, 2020, 31, 1313-1319.	1.8	11
44	Enzyme Release from Polyion Complex by Extremely Low Frequency Magnetic Field. Scientific Reports, 2020, 10, 4745.	1.6	9
45	Room temperature synthesized solid solution AuFe nanoparticles and their transformation into Au/Fe Janus nanocrystals. Nanoscale, 2021, 13, 10402-10413.	2.8	8
46	Permeability of the Composite Magnetic Microcapsules Triggered by a Non-Heating Low-Frequency Magnetic Field. Pharmaceutics, 2022, 14, 65.	2.0	7
47	Modulation of Î±-Chymotrypsin Conjugated to Magnetic Nanoparticles by the Non-Heating Low-Frequency Magnetic Field: Molecular Dynamics, Reaction Kinetics, and Spectroscopy Analysis. ACS Omega, 2022, 7, 20644-20655.	1.6	6
48	Mechanisms and conditions for mechanical activation of magnetic nanoparticles by external magnetic field for biomedical applications. Journal of Magnetism and Magnetic Materials, 2022, 553, 169278.	1.0	5
49	High Hydrostatic Pressure and Enzymology. , 1999, , 423-436.		3
50	Synthesis of allobetulin-based asialoglycoprotein receptor-targeted glycoconjugates. Mendeleev Communications, 2019, 29, 526-528.	0.6	1